News & Events

May 24, 2018

Autism Prevalence – Examining the Myths and Truths – Video Transcript

Transcript of Video Heidi Roger: Hi. I’m Heidi Roger. I am a board of director for SafeMinds, and I am the mom of a 23-year-old man with autism. Today, we’re speaking with Dr. Walter Zahorodny, the associate professor of pediatrics at the New Jersey Medical School at Rutgers University, and director of the New Jersey […]

April 26, 2018

U.S. Autism Prevalence Rate Soars to 1 in 59 Children

National Autism Organizations Demand Emergency Meeting with Secretary of Health and Human Services and Federal Autism Coordinator to Address Crisis Related Links Letter to HHS Officials CDC Report: Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years – Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014 Baltimore, MD, April 26, 2018 – SafeMinds, […]

April 26, 2018

Letter to HHS Officials

The Honorable Alex Azar Secretary, U.S. Department of Health and Human Services 200 Independence Avenue, S.W. Washington, DC 20201 Dr. Ann Wagner, Ph.D. Federal Autism Coordinator Chief, Biomarker and Intervention Development for Childhood-Onset Mental Disorders Branch Division of Translational Research National Institute of Mental Health 6001 Executive Blvd., Room 7162, MSC 9617 Bethesda, MD 20892 […]

April 23, 2018

Cannabis May Have Therapeutic Benefit for Autism, Should Have Fewer Federal Restrictions

The U.S. Food and Drug Administration (FDA) and the World Heath Organization (WHO) are now reviewing whether to remove cannabis from the Schedule I Controlled Substance List. Since cannabis may have potential as a therapeutic for people with autism, SafeMinds has submitted comments to the FDA in support of reassigning cannabis to a less restricted […]

April 23, 2018

SafeMinds Comments to FDA on Cannabis & Autism

Controlled Substance Staff Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 51, Rm. 5150 Silver Spring, MD 20993-0002 RE: Docket No. FDA-2018-N-1072 for “International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; Cannabis Plant and Resin; Extracts and Tinctures of Cannabis; Delta-9-Tetrahydrocannabinol (THC); Stereoisomers of […]

April 23, 2018

Two Treatments with Positive Results and the High Cost of Autism

Two abstracts being presented this week at the annual conference of the American Academy of Neurology report positive outcomes from two treatments for autism. A third article on healthcare utilization reports double the cost for adults with autism. A MitoCocktail was tested in eleven children with autism and mitocondrial (mt) dysfunction. Mt dysfunction is common in autism. The MitoCocktail contained carnitine, coenzyme Q10 and alpha-lipoic acid. Investigators Craig Newschaffer and colleagues at Drexel University conclude: “This small pilot study supports the hypothesis that in ASD MitoCocktail may have a therapeutic benefit, improving mt function and maladaptive behavior and speech. Larger placebo-controlled trials are needed to demonstrate efficacy.”

Show Buttons
Hide Buttons